[go: up one dir, main page]

PE20080180A1 - Preparacion oral de pioglitazona - Google Patents

Preparacion oral de pioglitazona

Info

Publication number
PE20080180A1
PE20080180A1 PE2007000630A PE2007000630A PE20080180A1 PE 20080180 A1 PE20080180 A1 PE 20080180A1 PE 2007000630 A PE2007000630 A PE 2007000630A PE 2007000630 A PE2007000630 A PE 2007000630A PE 20080180 A1 PE20080180 A1 PE 20080180A1
Authority
PE
Peru
Prior art keywords
pioglitazone
oral preparation
azucre
oral composition
talelact
Prior art date
Application number
PE2007000630A
Other languages
English (en)
Inventor
Kazuhiro Okochi
Hiroyoshi Koyama
Arisa Shingaki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38294162&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080180(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20080180A1 publication Critical patent/PE20080180A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)

Abstract

REFERIDA A UNA COMPOSICION ORAL EN FORMA DE TABLETA QUE COMPRENDE PIOGLITAZONA O UNA SAL DE LA MISMA Y UN CLORURO DE METAL ALCALINO TAL COMO EL CLORURO DE SODIO, DONDE LAS PARTICULAS QUE COMPRENDEN PIOGLITAZONA SON RECUBIERTAS CON SACARIDO TAL COMO AZUCAR, LACTOSA, MIEL, ENTRE OTROS. DICHA COMPOSICION ORAL ENMASCARA EL SABOR AMARGO DE LA PIOGLITAZONA
PE2007000630A 2006-05-23 2007-05-22 Preparacion oral de pioglitazona PE20080180A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006143390 2006-05-23

Publications (1)

Publication Number Publication Date
PE20080180A1 true PE20080180A1 (es) 2008-04-22

Family

ID=38294162

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000630A PE20080180A1 (es) 2006-05-23 2007-05-22 Preparacion oral de pioglitazona

Country Status (14)

Country Link
US (1) US8865217B2 (es)
EP (1) EP2019669B1 (es)
JP (1) JP5162475B2 (es)
KR (1) KR20090024181A (es)
CN (2) CN103520158B (es)
AR (1) AR061070A1 (es)
AT (1) ATE534374T1 (es)
CA (1) CA2653786C (es)
CL (1) CL2007001457A1 (es)
ES (1) ES2377839T3 (es)
MY (1) MY146781A (es)
PE (1) PE20080180A1 (es)
TW (1) TWI407959B (es)
WO (1) WO2007136129A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
US20120058205A1 (en) * 2009-03-04 2012-03-08 Walter Howard Peschel Compositions and treatment regimes for reducing inflammation, end-organ injury, and/or systemic endotoxemia
JPWO2010119851A1 (ja) * 2009-04-14 2012-10-22 ライオン株式会社 口腔内崩壊錠
WO2011074961A1 (en) * 2009-12-18 2011-06-23 Frieslandcampina Nederland Holding B.V. Co-processed tablet excipient composition its preparation and use
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
JP5630902B2 (ja) * 2010-08-26 2014-11-26 沢井製薬株式会社 ゾルピデム酒石酸塩含有口腔内崩壊錠の製造方法
JP5973347B2 (ja) * 2010-08-31 2016-08-23 協和発酵キリン株式会社 口腔内崩壊錠
WO2013129436A1 (ja) * 2012-02-29 2013-09-06 武田薬品工業株式会社 経口剤
US8969581B2 (en) 2013-03-14 2015-03-03 Deuterx, Llc 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
ES2831326T3 (es) 2014-01-15 2021-06-08 Poxel Sa Métodos para tratar trastornos neurológicos, metabólicos y otros mediante el uso de pioglitazona enantiopura enriquecida con deuterio
JP6574556B2 (ja) * 2014-08-27 2019-09-11 日東電工株式会社 口腔内フィルム状基剤及び製剤
CN104174022B (zh) * 2014-09-16 2018-10-16 过冬 一种吡格列酮的苦味抑制剂和包含吡格列酮的口服制剂
JP2018012697A (ja) * 2016-07-11 2018-01-25 大原薬品工業株式会社 口腔内崩壊時間が短縮された、塩を含有する錠剤
US20210386726A1 (en) * 2020-06-11 2021-12-16 Chang Gung University Method for inhibiting coronavirus infection and replication
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2809301B2 (ja) * 1993-12-09 1998-10-08 田辺製薬株式会社 苦味隠蔽された経口投与製剤
CN1059320C (zh) * 1994-04-07 2000-12-13 段永聚 一种无糖型草珊瑚含片
WO2002030400A1 (fr) * 2000-10-06 2002-04-18 Takeda Chemical Industries, Ltd. Preparations solides
GB0027357D0 (en) * 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
WO2003026586A2 (en) * 2001-09-28 2003-04-03 Teva Pharmaceutical Industries Ltd. Pioglitazone hydrochloride
JP2003183162A (ja) * 2001-12-17 2003-07-03 Sumitomo Pharmaceut Co Ltd シメチジン経口製剤
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
AU2003213338A1 (en) 2002-03-14 2003-09-22 Daiichi Suntory Pharma Co., Ltd. Tablet containing pilsicainide hydrochloride (dry)
IL164154A0 (en) * 2002-03-21 2005-12-18 Teva Pharma Fine particle size pioglitazone
WO2004026241A2 (en) * 2002-09-20 2004-04-01 Andrx Labs Llc Multistage formulation containing a biguanide and thiazolidindione derivatives
KR20070011497A (ko) * 2004-05-11 2007-01-24 산텐 세이야꾸 가부시키가이샤 각결막 장해 치료제
CN1859917B (zh) * 2004-09-29 2011-08-03 森永乳业株式会社 用于改善高血糖的药物和食品或饮料
CN101384251B (zh) 2005-12-22 2014-09-03 武田药品工业株式会社 含胰岛素敏化剂的固体制剂
US8632808B2 (en) 2006-04-27 2014-01-21 Takeda Pharmaceutical Company Limited Taste-masking solid preparation of pioglitazone

Also Published As

Publication number Publication date
CN101489538B (zh) 2014-01-08
EP2019669B1 (en) 2011-11-23
TWI407959B (zh) 2013-09-11
AR061070A1 (es) 2008-07-30
CN101489538A (zh) 2009-07-22
US8865217B2 (en) 2014-10-21
KR20090024181A (ko) 2009-03-06
TW200806332A (en) 2008-02-01
MY146781A (en) 2012-09-28
ES2377839T3 (es) 2012-04-02
CA2653786C (en) 2014-09-23
JP5162475B2 (ja) 2013-03-13
EP2019669A1 (en) 2009-02-04
WO2007136129A1 (en) 2007-11-29
JP2009538268A (ja) 2009-11-05
ATE534374T1 (de) 2011-12-15
CN103520158A (zh) 2014-01-22
HK1129566A1 (en) 2009-12-04
US20100136122A1 (en) 2010-06-03
CL2007001457A1 (es) 2008-01-04
CA2653786A1 (en) 2007-11-29
CN103520158B (zh) 2016-02-03

Similar Documents

Publication Publication Date Title
PE20080180A1 (es) Preparacion oral de pioglitazona
USD767438S1 (en) Jewelry pendant
USD722519S1 (en) Jewelry article for use as a pendant or chain
NO2018028I2 (no) Kombinasjonen alogliptin og pioglitazon, hver eventuelt i form av et farmasøytisk akseptabelt salt derav
FR2883179B1 (fr) Comprime enrobe
AR078417A1 (es) Composiciones de pelicula sublingual y bucal
AR096975A1 (es) Formulación líquida en aerosol de un artículo electrónico para fumar
ZA200906498B (en) Improved oral compositions comprising zinc citrate and/or tocopherol agents
JP2009531457A5 (es)
AU313327S (en) Toothbrush
PH12015501239A1 (en) Oral care products comprising tetrabasic zinc chloride and trimethylglycine
RU2004132636A (ru) Средство, обладающее антимикробной активностью
ECSP10010576A (es) Formulaciones orales e inyectables de compuestos de tetraciclina
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
MX365216B (es) Forma de dosificacion por via oral de difenhidramina de disolucion rapida.
CA2927016C (en) Oral care composition
NO20053091D0 (no) Samordnet oppforsel i mal-styrte lister.
PE20130147A1 (es) Combinacion farmaceutica de teobromina y un agente antitusivo no opioide
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych
CL2015001940A1 (es) Formulación que comprende un compuesto de benzotiazolona.
AR067498A1 (es) Composicion farmaceutica estable de una sal hidrosoluble de vinorrelbina
ECSP11011212A (es) Nueva asociación de ingredientes activos que contienen un fármaco antiinflamatorio, no esteroideo y un derivado de colchicósido
ECSP066713A (es) Forma de dosis solida
TWD193541S (zh) 寶石
EP1849774A4 (en) CYCLOHEPTA (B) PYRIDINE-3-CARBONYLGUANIDINE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING THEREOF

Legal Events

Date Code Title Description
FC Refusal